To include your compound in the COVID-19 Resource Center, submit it here.

Cytheris cancer news

Cytheris said the Cancer Immunotherapy Trials Network (CITN) selected CYT107

Read the full 102 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE